In an exciting development for DIPG research, Abbie’s Army has joined the DIPG/DMG Collaborative as Leadership Partners. This marks our second involvement with the collaborative, having first partnered back in 2013. Once again, Abbie’s Army proudly represents the UK as the only European member, working alongside foundations from the United States and Australia.
Leading International Research for DIPG
Research into rare cancers like DIPG (Diffuse Intrinsic Pontine Glioma) requires a global approach. By joining forces and pooling resources into international research initiatives, we can make faster progress toward eradicating DIPG. The collaboration ensures a coordinated strategy that maximises research efforts worldwide.
Maximizing Impact and Resources
One of the key benefits of this partnership is transparency in research funding, which helps prevent duplication of efforts, especially given the scarce financial resources dedicated to DIPG research. This streamlined approach allows all involved foundations to focus on the most promising pre-clinical and translational research opportunities.
A Growing Collaborative
The DIPG/DMG Collaborative is now comprised of over 25 foundations, all committed to inspiring research and funding millions of dollars towards finding a cure for DIPG and DMG (Diffuse Midline Glioma). Through this collaboration, Abbie’s Army will be recognised on all funded grants, further amplifying the charity’s impact on an international stage.
Looking Ahead: 2025 DIPG/DMG Symposium
The next major event for the Collaborative will be the DIPG/DMG Symposium, set to take place in Alberta, Canada, in 2025. This biannual event will showcase research developments and offer unique perspectives from experts around the globe, marking the culmination of the Collaborative’s funding cycle.
Abbie’s Army is excited to be part of this global movement and looks forward to the future advancements that will come from working together.
Comentários